PubMed:10945470 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":74},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":75,"end":268},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":269,"end":425},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":426,"end":553},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":554,"end":902},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":903,"end":1032},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":1033,"end":1156},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1157,"end":1251},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":1252,"end":1322},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":1323,"end":1399},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":1400,"end":1533},"obj":"Sentence"},{"id":"TextSentencer_T12","span":{"begin":1534,"end":1667},"obj":"Sentence"},{"id":"TextSentencer_T13","span":{"begin":1668,"end":1840},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":74},"obj":"Sentence"},{"id":"T2","span":{"begin":75,"end":268},"obj":"Sentence"},{"id":"T3","span":{"begin":269,"end":425},"obj":"Sentence"},{"id":"T4","span":{"begin":426,"end":553},"obj":"Sentence"},{"id":"T5","span":{"begin":554,"end":902},"obj":"Sentence"},{"id":"T6","span":{"begin":903,"end":1032},"obj":"Sentence"},{"id":"T7","span":{"begin":1033,"end":1156},"obj":"Sentence"},{"id":"T8","span":{"begin":1157,"end":1251},"obj":"Sentence"},{"id":"T9","span":{"begin":1252,"end":1322},"obj":"Sentence"},{"id":"T10","span":{"begin":1323,"end":1399},"obj":"Sentence"},{"id":"T11","span":{"begin":1400,"end":1533},"obj":"Sentence"},{"id":"T12","span":{"begin":1534,"end":1667},"obj":"Sentence"},{"id":"T13","span":{"begin":1668,"end":1840},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.\nOncogenic hypophosphatemic osteomalacia (OHO) is characterized by a renal phosphate leak, hypophosphatemia, low-serum calcitriol (1,25-vitamin-D3), and abnormalities in skeletal mineralization. Resection of OHO tumors results in remission of the symptoms, and there is evidence that a circulating phosphaturic factor plays a role in the bone disease. This paper describes the characterization and cloning of a gene that is a candidate for the tumor-secreted phosphaturic factor. This new gene has been named MEPE (matrix extracellular phosphoglycoprotein) and has major similarities to a group of bone-tooth mineral matrix phospho-glycoproteins (osteopontin (OPN; HGMW-approved symbol SPP1), dentin sialo phosphoprotein (DSPP), dentin matrix protein 1 (DMP1), bone sialoprotein II (IBSP), and bone morphogenetic proteins (BMP). All the proteins including MEPE contain RGD sequence motifs that are proposed to be essential for integrin-receptor interactions. Of further interest is the finding that MEPE, OPN, DSPP, DMP1, IBSP, and BMP3 all map to a defined region in chromosome 4q. Refined mapping localizes MEPE to 4q21.1 between ESTs D4S2785 (WI-6336) and D4S2844 (WI-3770). MEPE is 525 residues in length with a short N-terminal signal peptide. High-level expression of MEPE mRNA occurred in all four OHO tumors screened. Three of 11 non-OHO tumors screened contained trace levels of MEPE expression (detected only after RT-PCR and Southern 32P analysis). Normal tissue expression was found in bone marrow and brain with very-low-level expression found in lung, kidney, and human placenta. Evidence is also presented for the tumor secretion of clusterin (HGMW-approved symbol CLU) and its possible role as a cytotoxic factor in one of the OHO patients described."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":1588,"end":1593},"obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":1541,"end":1547},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":1634,"end":1638},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":30,"end":41},"obj":"http://purl.obolibrary.org/obo/UBERON_0002371"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":1572,"end":1583},"obj":"http://purl.obolibrary.org/obo/UBERON_0002371"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":187,"end":192},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T7","span":{"begin":767,"end":773},"obj":"http://purl.obolibrary.org/obo/UBERON_0001751"},{"id":"PD-UBERON-AE-B_T8","span":{"begin":803,"end":809},"obj":"http://purl.obolibrary.org/obo/UBERON_0001751"},{"id":"PD-UBERON-AE-B_T9","span":{"begin":1640,"end":1646},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"PD-UBERON-AE-B_T10","span":{"begin":1658,"end":1666},"obj":"http://purl.obolibrary.org/obo/UBERON_0001987"}],"text":"MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.\nOncogenic hypophosphatemic osteomalacia (OHO) is characterized by a renal phosphate leak, hypophosphatemia, low-serum calcitriol (1,25-vitamin-D3), and abnormalities in skeletal mineralization. Resection of OHO tumors results in remission of the symptoms, and there is evidence that a circulating phosphaturic factor plays a role in the bone disease. This paper describes the characterization and cloning of a gene that is a candidate for the tumor-secreted phosphaturic factor. This new gene has been named MEPE (matrix extracellular phosphoglycoprotein) and has major similarities to a group of bone-tooth mineral matrix phospho-glycoproteins (osteopontin (OPN; HGMW-approved symbol SPP1), dentin sialo phosphoprotein (DSPP), dentin matrix protein 1 (DMP1), bone sialoprotein II (IBSP), and bone morphogenetic proteins (BMP). All the proteins including MEPE contain RGD sequence motifs that are proposed to be essential for integrin-receptor interactions. Of further interest is the finding that MEPE, OPN, DSPP, DMP1, IBSP, and BMP3 all map to a defined region in chromosome 4q. Refined mapping localizes MEPE to 4q21.1 between ESTs D4S2785 (WI-6336) and D4S2844 (WI-3770). MEPE is 525 residues in length with a short N-terminal signal peptide. High-level expression of MEPE mRNA occurred in all four OHO tumors screened. Three of 11 non-OHO tumors screened contained trace levels of MEPE expression (detected only after RT-PCR and Southern 32P analysis). Normal tissue expression was found in bone marrow and brain with very-low-level expression found in lung, kidney, and human placenta. Evidence is also presented for the tumor secretion of clusterin (HGMW-approved symbol CLU) and its possible role as a cytotoxic factor in one of the OHO patients described."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":102,"end":114},"obj":"HP_0002749"},{"id":"T2","span":{"begin":165,"end":181},"obj":"HP_0002148"},{"id":"T3","span":{"begin":227,"end":252},"obj":"HP_0000924"},{"id":"T4","span":{"begin":286,"end":292},"obj":"HP_0002664"},{"id":"T5","span":{"begin":518,"end":523},"obj":"HP_0002664"},{"id":"T6","span":{"begin":1383,"end":1389},"obj":"HP_0002664"},{"id":"T7","span":{"begin":1420,"end":1426},"obj":"HP_0002664"},{"id":"T8","span":{"begin":1703,"end":1708},"obj":"HP_0002664"}],"text":"MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.\nOncogenic hypophosphatemic osteomalacia (OHO) is characterized by a renal phosphate leak, hypophosphatemia, low-serum calcitriol (1,25-vitamin-D3), and abnormalities in skeletal mineralization. Resection of OHO tumors results in remission of the symptoms, and there is evidence that a circulating phosphaturic factor plays a role in the bone disease. This paper describes the characterization and cloning of a gene that is a candidate for the tumor-secreted phosphaturic factor. This new gene has been named MEPE (matrix extracellular phosphoglycoprotein) and has major similarities to a group of bone-tooth mineral matrix phospho-glycoproteins (osteopontin (OPN; HGMW-approved symbol SPP1), dentin sialo phosphoprotein (DSPP), dentin matrix protein 1 (DMP1), bone sialoprotein II (IBSP), and bone morphogenetic proteins (BMP). All the proteins including MEPE contain RGD sequence motifs that are proposed to be essential for integrin-receptor interactions. Of further interest is the finding that MEPE, OPN, DSPP, DMP1, IBSP, and BMP3 all map to a defined region in chromosome 4q. Refined mapping localizes MEPE to 4q21.1 between ESTs D4S2785 (WI-6336) and D4S2844 (WI-3770). MEPE is 525 residues in length with a short N-terminal signal peptide. High-level expression of MEPE mRNA occurred in all four OHO tumors screened. Three of 11 non-OHO tumors screened contained trace levels of MEPE expression (detected only after RT-PCR and Southern 32P analysis). Normal tissue expression was found in bone marrow and brain with very-low-level expression found in lung, kidney, and human placenta. Evidence is also presented for the tumor secretion of clusterin (HGMW-approved symbol CLU) and its possible role as a cytotoxic factor in one of the OHO patients described."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"10945470-0#0#4#gene56955","span":{"begin":0,"end":4},"obj":"gene56955"},{"id":"10945470-0#61#73#diseaseC3887650","span":{"begin":61,"end":73},"obj":"diseaseC3887650"}],"relations":[{"id":"0#4#gene5695561#73#diseaseC3887650","pred":"associated_with","subj":"10945470-0#0#4#gene56955","obj":"10945470-0#61#73#diseaseC3887650"}],"text":"MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.\nOncogenic hypophosphatemic osteomalacia (OHO) is characterized by a renal phosphate leak, hypophosphatemia, low-serum calcitriol (1,25-vitamin-D3), and abnormalities in skeletal mineralization. Resection of OHO tumors results in remission of the symptoms, and there is evidence that a circulating phosphaturic factor plays a role in the bone disease. This paper describes the characterization and cloning of a gene that is a candidate for the tumor-secreted phosphaturic factor. This new gene has been named MEPE (matrix extracellular phosphoglycoprotein) and has major similarities to a group of bone-tooth mineral matrix phospho-glycoproteins (osteopontin (OPN; HGMW-approved symbol SPP1), dentin sialo phosphoprotein (DSPP), dentin matrix protein 1 (DMP1), bone sialoprotein II (IBSP), and bone morphogenetic proteins (BMP). All the proteins including MEPE contain RGD sequence motifs that are proposed to be essential for integrin-receptor interactions. Of further interest is the finding that MEPE, OPN, DSPP, DMP1, IBSP, and BMP3 all map to a defined region in chromosome 4q. Refined mapping localizes MEPE to 4q21.1 between ESTs D4S2785 (WI-6336) and D4S2844 (WI-3770). MEPE is 525 residues in length with a short N-terminal signal peptide. High-level expression of MEPE mRNA occurred in all four OHO tumors screened. Three of 11 non-OHO tumors screened contained trace levels of MEPE expression (detected only after RT-PCR and Southern 32P analysis). Normal tissue expression was found in bone marrow and brain with very-low-level expression found in lung, kidney, and human placenta. Evidence is also presented for the tumor secretion of clusterin (HGMW-approved symbol CLU) and its possible role as a cytotoxic factor in one of the OHO patients described."}

{"project":"PubCasesHPO","denotations":[{"id":"AB1","span":{"begin":102,"end":114},"obj":"HP:0002749"},{"id":"TI1","span":{"begin":61,"end":73},"obj":"HP:0002749"},{"id":"AB2","span":{"begin":165,"end":181},"obj":"HP:0002148"},{"id":"AB3","span":{"begin":183,"end":203},"obj":"HP:0012052"}],"text":"MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.\nOncogenic hypophosphatemic osteomalacia (OHO) is characterized by a renal phosphate leak, hypophosphatemia, low-serum calcitriol (1,25-vitamin-D3), and abnormalities in skeletal mineralization. Resection of OHO tumors results in remission of the symptoms, and there is evidence that a circulating phosphaturic factor plays a role in the bone disease. This paper describes the characterization and cloning of a gene that is a candidate for the tumor-secreted phosphaturic factor. This new gene has been named MEPE (matrix extracellular phosphoglycoprotein) and has major similarities to a group of bone-tooth mineral matrix phospho-glycoproteins (osteopontin (OPN; HGMW-approved symbol SPP1), dentin sialo phosphoprotein (DSPP), dentin matrix protein 1 (DMP1), bone sialoprotein II (IBSP), and bone morphogenetic proteins (BMP). All the proteins including MEPE contain RGD sequence motifs that are proposed to be essential for integrin-receptor interactions. Of further interest is the finding that MEPE, OPN, DSPP, DMP1, IBSP, and BMP3 all map to a defined region in chromosome 4q. Refined mapping localizes MEPE to 4q21.1 between ESTs D4S2785 (WI-6336) and D4S2844 (WI-3770). MEPE is 525 residues in length with a short N-terminal signal peptide. High-level expression of MEPE mRNA occurred in all four OHO tumors screened. Three of 11 non-OHO tumors screened contained trace levels of MEPE expression (detected only after RT-PCR and Southern 32P analysis). Normal tissue expression was found in bone marrow and brain with very-low-level expression found in lung, kidney, and human placenta. Evidence is also presented for the tumor secretion of clusterin (HGMW-approved symbol CLU) and its possible role as a cytotoxic factor in one of the OHO patients described."}

{"project":"PubCasesORDO","denotations":[{"id":"AB1","span":{"begin":75,"end":114},"obj":"ORDO:352540"}],"namespaces":[{"prefix":"ORDO","uri":"http://www.orpha.net/ORDO/Orphanet_"}],"text":"MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.\nOncogenic hypophosphatemic osteomalacia (OHO) is characterized by a renal phosphate leak, hypophosphatemia, low-serum calcitriol (1,25-vitamin-D3), and abnormalities in skeletal mineralization. Resection of OHO tumors results in remission of the symptoms, and there is evidence that a circulating phosphaturic factor plays a role in the bone disease. This paper describes the characterization and cloning of a gene that is a candidate for the tumor-secreted phosphaturic factor. This new gene has been named MEPE (matrix extracellular phosphoglycoprotein) and has major similarities to a group of bone-tooth mineral matrix phospho-glycoproteins (osteopontin (OPN; HGMW-approved symbol SPP1), dentin sialo phosphoprotein (DSPP), dentin matrix protein 1 (DMP1), bone sialoprotein II (IBSP), and bone morphogenetic proteins (BMP). All the proteins including MEPE contain RGD sequence motifs that are proposed to be essential for integrin-receptor interactions. Of further interest is the finding that MEPE, OPN, DSPP, DMP1, IBSP, and BMP3 all map to a defined region in chromosome 4q. Refined mapping localizes MEPE to 4q21.1 between ESTs D4S2785 (WI-6336) and D4S2844 (WI-3770). MEPE is 525 residues in length with a short N-terminal signal peptide. High-level expression of MEPE mRNA occurred in all four OHO tumors screened. Three of 11 non-OHO tumors screened contained trace levels of MEPE expression (detected only after RT-PCR and Southern 32P analysis). Normal tissue expression was found in bone marrow and brain with very-low-level expression found in lung, kidney, and human placenta. Evidence is also presented for the tumor secretion of clusterin (HGMW-approved symbol CLU) and its possible role as a cytotoxic factor in one of the OHO patients described."}

{"project":"UBERON-AE","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":30,"end":41},"obj":"http://purl.obolibrary.org/obo/UBERON_0002371"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":1572,"end":1583},"obj":"http://purl.obolibrary.org/obo/UBERON_0002371"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":187,"end":192},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":767,"end":773},"obj":"http://purl.obolibrary.org/obo/UBERON_0001751"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":803,"end":809},"obj":"http://purl.obolibrary.org/obo/UBERON_0001751"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":1541,"end":1547},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"PD-UBERON-AE-B_T7","span":{"begin":1588,"end":1593},"obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"PD-UBERON-AE-B_T8","span":{"begin":1634,"end":1638},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"PD-UBERON-AE-B_T9","span":{"begin":1640,"end":1646},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"PD-UBERON-AE-B_T10","span":{"begin":1658,"end":1666},"obj":"http://purl.obolibrary.org/obo/UBERON_0001987"}],"text":"MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.\nOncogenic hypophosphatemic osteomalacia (OHO) is characterized by a renal phosphate leak, hypophosphatemia, low-serum calcitriol (1,25-vitamin-D3), and abnormalities in skeletal mineralization. Resection of OHO tumors results in remission of the symptoms, and there is evidence that a circulating phosphaturic factor plays a role in the bone disease. This paper describes the characterization and cloning of a gene that is a candidate for the tumor-secreted phosphaturic factor. This new gene has been named MEPE (matrix extracellular phosphoglycoprotein) and has major similarities to a group of bone-tooth mineral matrix phospho-glycoproteins (osteopontin (OPN; HGMW-approved symbol SPP1), dentin sialo phosphoprotein (DSPP), dentin matrix protein 1 (DMP1), bone sialoprotein II (IBSP), and bone morphogenetic proteins (BMP). All the proteins including MEPE contain RGD sequence motifs that are proposed to be essential for integrin-receptor interactions. Of further interest is the finding that MEPE, OPN, DSPP, DMP1, IBSP, and BMP3 all map to a defined region in chromosome 4q. Refined mapping localizes MEPE to 4q21.1 between ESTs D4S2785 (WI-6336) and D4S2844 (WI-3770). MEPE is 525 residues in length with a short N-terminal signal peptide. High-level expression of MEPE mRNA occurred in all four OHO tumors screened. Three of 11 non-OHO tumors screened contained trace levels of MEPE expression (detected only after RT-PCR and Southern 32P analysis). Normal tissue expression was found in bone marrow and brain with very-low-level expression found in lung, kidney, and human placenta. Evidence is also presented for the tumor secretion of clusterin (HGMW-approved symbol CLU) and its possible role as a cytotoxic factor in one of the OHO patients described."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":1722,"end":1731},"obj":"gene:1191"},{"id":"T1","span":{"begin":1817,"end":1820},"obj":"disease:C0029442"},{"id":"T2","span":{"begin":1754,"end":1757},"obj":"gene:1191"},{"id":"T3","span":{"begin":1817,"end":1820},"obj":"disease:C0029442"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.\nOncogenic hypophosphatemic osteomalacia (OHO) is characterized by a renal phosphate leak, hypophosphatemia, low-serum calcitriol (1,25-vitamin-D3), and abnormalities in skeletal mineralization. Resection of OHO tumors results in remission of the symptoms, and there is evidence that a circulating phosphaturic factor plays a role in the bone disease. This paper describes the characterization and cloning of a gene that is a candidate for the tumor-secreted phosphaturic factor. This new gene has been named MEPE (matrix extracellular phosphoglycoprotein) and has major similarities to a group of bone-tooth mineral matrix phospho-glycoproteins (osteopontin (OPN; HGMW-approved symbol SPP1), dentin sialo phosphoprotein (DSPP), dentin matrix protein 1 (DMP1), bone sialoprotein II (IBSP), and bone morphogenetic proteins (BMP). All the proteins including MEPE contain RGD sequence motifs that are proposed to be essential for integrin-receptor interactions. Of further interest is the finding that MEPE, OPN, DSPP, DMP1, IBSP, and BMP3 all map to a defined region in chromosome 4q. Refined mapping localizes MEPE to 4q21.1 between ESTs D4S2785 (WI-6336) and D4S2844 (WI-3770). MEPE is 525 residues in length with a short N-terminal signal peptide. High-level expression of MEPE mRNA occurred in all four OHO tumors screened. Three of 11 non-OHO tumors screened contained trace levels of MEPE expression (detected only after RT-PCR and Southern 32P analysis). Normal tissue expression was found in bone marrow and brain with very-low-level expression found in lung, kidney, and human placenta. Evidence is also presented for the tumor secretion of clusterin (HGMW-approved symbol CLU) and its possible role as a cytotoxic factor in one of the OHO patients described."}